Pembrolizumab for Early Triple-Negative Breast Cancer. Reply
- PMID: 32579835
- DOI: 10.1056/NEJMc2006684
Pembrolizumab for Early Triple-Negative Breast Cancer. Reply
Comment on
-
Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med. 2020 Jun 25;382(26):e108. doi: 10.1056/NEJMc2006684. N Engl J Med. 2020. PMID: 32579834 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical